VentureMed Names Jordan Knepper as CMO and Announces Study Results for Flex VP System

March 14, 2025—VentureMed Group, Inc., a medical device company focused on arteriovenous access and peripheral arterial disease, recently announced the appointment of Jordan Knepper, MD, as Chief Medical Officer.

According to VentureMed, Dr. Knepper is a vascular surgeon and Associate Professor of Surgery at Michigan State University in East Lansing, Michigan. Dr. Knepper succeeds John Pigott, MD, who remains as Founder & Critical Advisor.

The company also announced findings from the BELONG study of the company’s Flex vessel prep (VP) system with drug-coated balloons to treat peripheral vascular disease.

The investigator-initiated study was led by Daniel Périard, MD, at HFR-Hôpital Cantonal Fribourg in Fribourg, Switzerland. The 12-month results were published by Adeline Demierre, MD, et al online in Journal of Endovascular Therapy.

As summarized in VentureMed’s press release, the single-arm prospective trial was composed of 41 patients. The investigators reported 97.5% freedom from clinically driven target lesion revascularization and sustained symptom relief at 12 months.

The company stated that the BELONG results suggest that vessel preparation using Flex VP with a drug-coated balloon provides significant long-term benefits for patients with highly calcified lesions of the superficial femoral artery or popliteal artery.

VentureMed’s Flex VP system uses the company’s kinetic endovascular micro-incision creation (KEMIC) technology. KEMIC leverages controlled motion and dynamic vessel apposition to create long, precise micro-incisions. Flex VP has received FDA 510(k) clearance and CE Mark approval, advised the company.

The company also announced the expansion of its sales and marketing leadership team to focus on expanding commercialization of the Flex VP system across the United States and select European markets; enhancing United States reimbursement strategies; and scaling manufacturing to meet anticipated market growth.